Serum selenium is low in newly diagnosed Graves’ disease: a population-based study

TY - JOUR

T1 - Serum selenium is low in newly diagnosed Graves’ disease

T2 - a population-based study

AU - Bülow Pedersen, Inge

AU - Knudsen, Nils

AU - Carlé, Allan

AU - Schomburg, Lutz

AU - Köhrle, Josef

AU - Jørgensen, Torben

AU - Rasmussen, Lone Banke

AU - Ovesen, Lars

AU - Laurberg, Peter Marsvin

PY - 2013/10

Y1 - 2013/10

N2 - Context Selenium deficiency may play an important role in the initiation and progression of autoimmune thyroid disease. Objective To compare serum selenium (s-Se) values in patients with newly diagnosed autoimmune thyroid disease and controls from the Danish population. Design and settings S-Se was measured in triplicate by a fluorimetric method. Participants Patients with newly diagnosed Graves' disease (GD) (n = 97) or autoimmune overt hypothyroidism (AIH) (n = 96), euthyroid subjects with high serum levels of thyroid peroxidase antibody (TPO-Ab) (TPO-Ab > 1500 U/ml, n = 92) and random controls (n = 830). Main outcome measure Differences in s-Se values. Results S-Se was lower in patients with GD than in controls (mean (SD), GD: 89·9 μg/l (18·4); controls: 98·8 μg/l (19·7), P < 0·01). This was confirmed in a multivariate logistic regression model adjusting for age, sex, mineral supplements, smoking, geographical region and time of sampling (P < 0·01). In a linear model, s-Se was similar in patients with AIH (mean (SD): 98·4 μg/l (24·9)) and in controls (P = 0·86). In the multivariate model however, s-Se was marginally lower in patients with AIH compared to controls (P = 0·04). There was no significant difference in s-Se between euthyroid participants with high TPO-Ab and random controls (linear: P = 0·97; multivariate: P = 0·27). Conclusion Patients with newly diagnosed GD and AIH had significantly lower s-Se compared with random controls. Our observation supports the postulated link between inadequate selenium supply and overt autoimmune thyroid disease, especially GD.

AB - Context Selenium deficiency may play an important role in the initiation and progression of autoimmune thyroid disease. Objective To compare serum selenium (s-Se) values in patients with newly diagnosed autoimmune thyroid disease and controls from the Danish population. Design and settings S-Se was measured in triplicate by a fluorimetric method. Participants Patients with newly diagnosed Graves' disease (GD) (n = 97) or autoimmune overt hypothyroidism (AIH) (n = 96), euthyroid subjects with high serum levels of thyroid peroxidase antibody (TPO-Ab) (TPO-Ab > 1500 U/ml, n = 92) and random controls (n = 830). Main outcome measure Differences in s-Se values. Results S-Se was lower in patients with GD than in controls (mean (SD), GD: 89·9 μg/l (18·4); controls: 98·8 μg/l (19·7), P < 0·01). This was confirmed in a multivariate logistic regression model adjusting for age, sex, mineral supplements, smoking, geographical region and time of sampling (P < 0·01). In a linear model, s-Se was similar in patients with AIH (mean (SD): 98·4 μg/l (24·9)) and in controls (P = 0·86). In the multivariate model however, s-Se was marginally lower in patients with AIH compared to controls (P = 0·04). There was no significant difference in s-Se between euthyroid participants with high TPO-Ab and random controls (linear: P = 0·97; multivariate: P = 0·27). Conclusion Patients with newly diagnosed GD and AIH had significantly lower s-Se compared with random controls. Our observation supports the postulated link between inadequate selenium supply and overt autoimmune thyroid disease, especially GD.

U2 - 10.1111/cen.12185

DO - 10.1111/cen.12185

M3 - Journal article

C2 - 23448365

SN - 0300-0664

VL - 79

SP - 584

EP - 590

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - 4

ER -